{
    "clinical_study": {
        "@rank": "35003", 
        "arm_group": {
            "arm_group_label": "CP-690,550", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "There were 2 study periods in this study.  In the Period 1, CP-690,550 was to be\n      administered approximately 1 to 2 hours following hemodialysis.  If significant non-renal\n      clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed\n      in Period 1, a second period (Period 2) will be conducted.  In Period 2, a single dose of\n      drug will be administered approximately 4 hours prior to hemodialysis."
        }, 
        "brief_title": "Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Includes all participants enrolled in the study.", 
                        "title": "Entire Study Population"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "12"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "7.9", 
                                            "@value": "45.9"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "2"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "10"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "AUC (0 - \u221e)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - \u221e). It is obtained from AUC (0 - t) plus AUC (t - \u221e).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "158", 
                                                    "@value": "396"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "AUC (0 - \u221e)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - \u221e). It is obtained from AUC (0 - t) plus AUC (t - \u221e).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)]", 
                                    "units": "nanogram*hour/milliliter (ng*hr/mL)"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hours (hrs) post-dose in Period 1", 
                        "title": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)]", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "151", 
                                                    "@value": "385"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                                    "units": "ng*hr/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1", 
                        "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "23.9", 
                                                    "@value": "106"
                                                }
                                            }
                                        }
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximum Observed Plasma Concentration (Cmax)", 
                                    "units": "nanogram/milliliter (ng/mL)"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1", 
                        "title": "Maximum Observed Plasma Concentration (Cmax)", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "0.5", 
                                                    "@upper_limit": "0.5", 
                                                    "@value": "0.5"
                                                }
                                            }
                                        }
                                    }, 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                                    "units": "hr"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1", 
                        "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "1.18", 
                                                    "@value": "3.46"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Plasma Decay Half-Life (t1/2)", 
                                    "units": "hr"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1", 
                        "title": "Plasma Decay Half-Life (t1/2)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "243", 
                                                    "@value": "501"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Oral Clearance (CLpo)", 
                                    "units": "milliliter/minute (mL/min)"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1", 
                        "title": "Oral Clearance (CLpo)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                                "title": "CP-690,550 (Period 2)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "11"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "124", 
                                                    "@value": "311"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Dialyser Clearance (CL HD) From 0 to 1 Hour", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 to 1 hrs during hemodialysis started 4 hrs post-dose in Period 2", 
                        "title": "Dialyser Clearance (CL HD) From 0 to 1 Hour", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                                "title": "CP-690,550 (Period 2)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "11"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "138", 
                                                    "@value": "325"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Dialyser Clearance (CL HD) From 1 to 2 Hour", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "1 to 2 hrs during hemodialysis started 4 hrs post-dose in Period 2", 
                        "title": "Dialyser Clearance (CL HD) From 1 to 2 Hour", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                                "title": "CP-690,550 (Period 2)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "135", 
                                                    "@value": "332"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Dialyser Clearance (CL HD) From 2 to 3 Hour", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "2 to 3 hrs during hemodialysis started 4 hrs post-dose in Period 2", 
                        "title": "Dialyser Clearance (CL HD) From 2 to 3 Hour", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                                "title": "CP-690,550 (Period 2)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "7"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "111", 
                                                    "@value": "292"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Dialyser Clearance (CL HD) From 3 to 4 Hour", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "3 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2", 
                        "title": "Dialyser Clearance (CL HD) From 3 to 4 Hour", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                                "title": "CP-690,550 (Period 1)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "11"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.042", 
                                                    "@value": "0.390"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Fraction of Unbound Drug (fu)", 
                                    "units": "ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "2 hours post-dose in Period 1", 
                        "title": "Fraction of Unbound Drug (fu)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                                "title": "CP-690,550 (Period 2)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "11"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "132", 
                                                    "@value": "318"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Overall Dialyser Clearance (CL HD)", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2", 
                        "title": "Overall Dialyser Clearance (CL HD)", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                                "title": "CP-690,550 (Period 2)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "2"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "200", 
                                                    "@value": "377"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Dialyser Clearance (CL HD) From 3 to 3.5 Hour", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "Analysis set included all participants who received study medication. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "3 to 3.5 hrs during hemodialysis started 4 hrs post-dose in Period 2", 
                        "title": "Dialyser Clearance (CL HD) From 3 to 3.5 Hour", 
                        "type": "Other Pre-specified"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Single oral dose of CP-690,550 10 milligram (mg) oral powder for constitution (OPC) 1 to 2 hours (hrs) post-hemodialysis in Period 1 followed by single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2. A washout period of at least 14 days was maintained between each intervention period.", 
                        "title": "CP-690,550 (10 mg OPC)"
                    }
                }, 
                "period_list": {
                    "period": [
                        {
                            "drop_withdraw_reason_list": {
                                "drop_withdraw_reason": {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Protocol Violation"
                                }
                            }, 
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "12", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "11", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "1", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Period 1"
                        }, 
                        {
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "11", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "11", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Washout Period (at Least 14 Days)"
                        }, 
                        {
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "11", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "11", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Period 2"
                        }
                    ]
                }
            }, 
            "point_of_contact": {
                "email": "ClinicalTrials.gov_Inquiries@pfizer.com", 
                "name_or_title": "Pfizer ClinicalTrials.gov Call Center", 
                "organization": "Pfizer, Inc.", 
                "phone": "1-800-718-1021"
            }, 
            "reported_events": {
                "desc": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.", 
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Single oral dose of CP-690,550 10 mg OPC 1 to 2 hours post-hemodialysis in Period 1.", 
                            "title": "CP-690,550 (Period 1)"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Single oral dose of CP-690,550 10 mg OPC approximately 4 hours prior to hemodialysis in Period 2.", 
                            "title": "CP-690,550 (Period 2)"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "12"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "11"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Ecchymosis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Thrombocytopenia"
                                        }
                                    ]
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "12"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "11"
                                            }
                                        ], 
                                        "sub_title": "Dyspepsia"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Headache"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Pain"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "12"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "11"
                                            }
                                        ], 
                                        "sub_title": "Hypoglycemia"
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Dizziness"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Paresthesia"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Cough increased"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "12"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "11"
                                                }
                                            ], 
                                            "sub_title": "Respiratory tract infection"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "COSTART", 
                    "frequency_threshold": "0"
                }
            }
        }, 
        "completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "End-Stage Renal Disease", 
            "Hemodialysis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with end-stage renal disease\n\n          -  Subjects need hemodialysis 3 times weekly\n\n        Exclusion Criteria:\n\n          -  Subjects with evidence or history of clinically significant disease, excluding those\n             common for subjects with End-Stage Renal Disease (ESRD).\n\n          -  Subjects with any condition possibly affecting drug absorption.\n\n          -  Subjects with malignancies with the exception of adequately treated basal cell\n             carcinoma of the skin."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "firstreceived_results_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710020", 
            "org_study_id": "A3921004"
        }, 
        "intervention": {
            "arm_group_label": "CP-690,550", 
            "description": "CP-690,550 10 mg oral powder for constitution", 
            "intervention_name": "CP-690,550", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "CP-690", 
            "550", 
            "pharmacokinetics", 
            "end-stage renal disease"
        ], 
        "lastchanged_date": "November 19, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921004&StudyName=Pharmacokinetics%20And%20Dialysability%20Of%20CP-690%2C550%20In%20Subjects%20With%20End-Stage%20Renal%20Disease"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis", 
        "other_outcome": [
            {
                "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                "measure": "Overall Dialyser Clearance (CL HD)", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2"
            }, 
            {
                "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                "measure": "Dialyser Clearance (CL HD) From 3 to 3.5 Hour", 
                "safety_issue": "No", 
                "time_frame": "3 to 3.5 hrs during hemodialysis started 4 hrs post-dose in Period 2"
            }
        ], 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - \u221e)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - \u221e). It is obtained from AUC (0 - t) plus AUC (t - \u221e).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)]", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hours (hrs) post-dose in Period 1"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.", 
                "measure": "Oral Clearance (CLpo)", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1"
            }, 
            {
                "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                "measure": "Dialyser Clearance (CL HD) From 0 to 1 Hour", 
                "safety_issue": "No", 
                "time_frame": "0 to 1 hrs during hemodialysis started 4 hrs post-dose in Period 2"
            }, 
            {
                "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                "measure": "Dialyser Clearance (CL HD) From 1 to 2 Hour", 
                "safety_issue": "No", 
                "time_frame": "1 to 2 hrs during hemodialysis started 4 hrs post-dose in Period 2"
            }, 
            {
                "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                "measure": "Dialyser Clearance (CL HD) From 2 to 3 Hour", 
                "safety_issue": "No", 
                "time_frame": "2 to 3 hrs during hemodialysis started 4 hrs post-dose in Period 2"
            }, 
            {
                "description": "Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu*Cmid*tm).", 
                "measure": "Dialyser Clearance (CL HD) From 3 to 4 Hour", 
                "safety_issue": "No", 
                "time_frame": "3 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.", 
            "measure": "Fraction of Unbound Drug (fu)", 
            "safety_issue": "No", 
            "time_frame": "2 hours post-dose in Period 1"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2003", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}